Friday, February 20, 2026
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
  • My Account
  • Log In
Daily Remedy
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Perspectives

Faulty Opioid Overdose Data

Daily Remedy by Daily Remedy
April 19, 2023
in Perspectives
0
Faulty Opioid Overdose Data

Daily Mirror

“The fault lies not in our stars, but in ourselves,” is a commonly referenced line from Shakespeare’s Julius Caesar. It means we’re responsible for our actions. Fate is just an excuse. When we apply this logic to data, we can just as well infer that the inputs we use and how we format the data tell more than the data itself.

This is particularly true for data on the opioid crisis. Currently, we’re enamored with mortality and overdose rates. We focus on these two because they’re easy to measure and readily available. But they are a poor gauge of the crisis.

Addiction is a complex and multifaceted condition. It’s challenging to accurately measure. It can involve both physical and psychological dependence. And it can manifest in different ways in different people. We still don’t have a consensus understanding of the term. What we call an addiction is really a dependency. Where one ends and the other begins is hotly contested. But that distinction matters. How an addiction forms matters more than how it ends. Yet we only focus on the most glaring outcomes. As a result, our focus diverts away from identifying more meaningful metrics.

Addiction is best explained as a series of decisions with social and clinical implications, all overlapping in complex, dynamic ways. To measure this, we have to challenge our notions of clinical data. We need new ways of thinking so we can create new metrics to measure.

This includes factors like the prevalence of social stigma in different areas and varying access to treatment centers. Some struggling with addiction are more likely to seek treatment but cannot due to a lack of availability, while others may have easy access to treatment but might be reluctant to seek help because of social stigma. In both cases, the patients are struggling with addiction, but the underlying behaviors are different, so the mode of treatment should be different as well.

These dynamic differences in behavior are only a part of the issue. The other is how we understand addiction as a medical condition. Surprisingly, it varies across the country.

These discrepancies lead to differing diagnostic criteria and classification systems of addiction. So patients receive varying quality of care in different regions. While the diagnostic criteria for addiction will change as our understanding of addiction evolves, it should change uniformly and according to clinical studies, not through inconsistent diagnostic patterns.

Never has it been more important to find new methods of measuring addiction. Opioid settlements have already begun disseminating, but few truly understand how it should be allocated. States designated committees to decide where funds should go, but so much remains unknown – because we still don’t know how to measure addiction.

The severity of this problem is exemplified in the following decision – which would net a greater benefit to a community, investing in a new treatment facility or offering more training for law enforcement. Unfortunately, there’s no consistent answer. Each community has different forms of addiction emerging out of unique patterns of behavior, even for communities afflicted with the same substance of abuse. In some communities, a new treatment facility would be useful. In others, greater access to harm reduction medications would be beneficial. There’s no single answer because that’s not how addiction works.

This may appear novel to some, but to those living through the opioid crisis, this is common knowledge. But, as the saying goes, common sense is anything but common. Those with the greatest insights, the lived experiences, are often the ones left out of key decisions.

If we don’t have input from those most affected by this crisis, then we risk using the same metrics with the same data models. It’s inevitable. Policy doesn’t change because the same decision-makers develop new ways of thinking. Policy changes with new input from new sources. But with the same decision-makers in place, we’ll have the same results. And they’ll justify their actions through their data.

It’s not the data’s fault. The fault lies with those who wrongly interpret and format the data. If we don’t include the input of those with lived experiences to improve how we measure data, then the fault will lie only in ourselves.

ShareTweet
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Comments 0

  1. Rachael Horning says:
    3 years ago

    It’s referred to as “Policy-Based Evidence,” and currently the Body of our Science is eaten with it.

    Reply
    • Anon md says:
      3 years ago

      What the heck does “policy-based evidence” mean?
      Oh wait, it doesn’t mean anything.

      I am genuinely confused. I think conflating addiction and pain has turned into a contagious disease which is epidemic. They mostly have nothing to do with one another. People prone to addiction have it before they take an opioid-ask them. People not prone won’t develop it no matter how long they’re on one or how bad their circumstances are. And pain is just its own thing, which deserves to be treated until the human experiencing it can function somewhat and the pain is somewhat relieved. Mix the concepts enough and people forget. Hyperalgesia and allodynia are hooey. Progressive disease is a thing. “Chronic” or supposed to have healed within 3 months and be pain free is a made up concept. Made up out of thin air just for this situation. Plenty of tissue takes 12-18 months or longer to heal; like discs, if it does, and that has not changed since I went to college and medical school and residency decades ago. This never gets mentioned though. Or the fact that severely damaged tissue may always hurt even when maximally healed. And sometimes the hurt is severe. Some people graduate at the bottom of the class. I guess those are the people allowed to make up this stuff because they obviously didn’t learn basic sciences. Gonna start saying it.

      Before I got a physical diagnosis I got depressed (actually, that’s not even correct-I had adjustment reaction to inappropriate treatment) and I sought treatment voluntarily. I was then kidnapped basically, and I got to see what they do to people with mental health and substance abuse issues. I was glad I wasn’t in the substance group, but what I got was bad enough. After the money is spent from suing pharma, the lawsuits will be directed at treatment factories, oh wait, facilities, for the abuse and trauma they are inflicting. I didn’t get better there, I got worse, but at least it led to such a severe injury I got closer to my real problem.

      Reply
  2. Paintabulous says:
    3 years ago

    “What we call an addiction is really a dependency.”
    What we call dependency; however, is not at all addiction.
    People in pain who become dependent on opioids to function are not addicted to these medications. On the contrary.
    Opioids allow people in pain to function without cravings, withdrawal, and other addictive behaviors.

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

This conversation focuses on debunking myths surrounding GLP-1 medications, particularly the misinformation about their association with pancreatic cancer. The speaker emphasizes the importance of understanding clinical study designs, especially the distinction between observational studies and randomized controlled trials. The discussion highlights the need for patients to critically evaluate the sources of information regarding medication side effects and to empower themselves in their healthcare decisions.

Takeaways
GLP-1 medications are not linked to pancreatic cancer.
Peer-reviewed studies debunk misinformation about GLP-1s.
Anecdotal evidence is not reliable for general conclusions.
Observational studies have limitations in generalizability.
Understanding study design is crucial for evaluating claims.
Symptoms should be discussed in the context of clinical conditions.
Not all side effects reported are relevant to every patient.
Observational studies can provide valuable insights but are context-specific.
Patients should critically assess the relevance of studies to their own experiences.
Engagement in discussions about specific studies can enhance understanding

Chapters
00:00
Debunking GLP-1 Medication Myths
02:56
Understanding Clinical Study Designs
05:54
The Role of Observational Studies in Healthcare
Debunking Myths About GLP-1 Medications
YouTube Video DM9Do_V6_sU
Subscribe

2027 Medicare Advantage & Part D Advance Notice

Clinical Reads

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

by Daily Remedy
February 15, 2026
0

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!

Twitter Updates

Tweets by TheDailyRemedy

Popular

  • The Prevention Gap in Dementia Care

    The Prevention Gap in Dementia Care

    0 shares
    Share 0 Tweet 0
  • Healthcare Natural Rights

    0 shares
    Share 0 Tweet 0
  • Healthcare in Space

    1 shares
    Share 0 Tweet 0
  • Heat Safety Tips Every Pregnant Mother Should Know

    0 shares
    Share 0 Tweet 0
  • What is the 411 on the New 988 Hotline?

    0 shares
    Share 0 Tweet 0
  • 628 Followers

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Join Our Newsletter!

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2026 Daily Remedy

No Result
View All Result
  • Home
  • Articles
  • Podcasts
  • Surveys
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner

© 2026 Daily Remedy